Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year. Explore more details here.

Amgen in November said MariTide helped patients with obesity lose up to 20% of their weight on average after a year in a phase two trial, with no weight loss plateau. The drug also helped patients ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea. The drug demonstrated 20% average ...

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market.

Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436) or 844-REPATHA (844-737-2842) regarding Repatha ® availability or find more information, including full Prescribing Information, at www ...